Insulin degludec
Ultralong-acting basal insulin analogue / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Tresiba?
Summarize this article for a 10 year old
Insulin degludec (INN/USAN) is an ultralong-acting basal insulin analogue that was developed by Novo Nordisk under the brand name Tresiba.[7] It is administered via subcutaneous injection to help control the blood sugar level of those with diabetes. It has a duration of action that lasts up to 42 hours (compared to 18 to 26 hours provided by other marketed long-acting insulins such as insulin glargine and insulin detemir), making it a once-daily basal insulin,[8][9][10] that is one that provides a base insulin level, as opposed to the fast- and short-acting bolus insulins.
Clinical data | |
---|---|
Trade names | Tresiba |
AHFS/Drugs.com | Monograph |
MedlinePlus | a615055 |
License data | |
Pregnancy category |
|
Routes of administration | Subcutaneous |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem SID | |
ChemSpider |
|
UNII | |
KEGG |
|
Chemical and physical data | |
Formula | C274H411N65O81S6 |
Molar mass | 6104.04 g·mol−1 |
NY (what is this?) (verify) |
Insulin degludec is a modified insulin that has one single amino acid deleted in comparison to human insulin, and is conjugated to hexadecanedioic acid via gamma-L-glutamyl spacer at the amino acid lysine at position B29.
It is included on the World Health Organization's List of Essential Medicines[11] as an equivalent to insulin glargine. In 2021, it was the 146th most commonly prescribed medication in the United States, with more than 4 million prescriptions.[12][13]